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Abstract Food intake and appetite are regulated by var-
ious circulating hormones including ghrelin and glucagon-
like-peptide 1 (GLP-1). Ghrelin, mainly released from the
stomach, increases food intake, induces appetite, enhances
adiposity as well as releases growth hormone. Hypotha-
lamic ‘‘ghrelin receptors’’ (GHS-R1A) have a critical role
in food intake regulation, but GHS-R1A are also expressed
in reward related areas. GLP-1 is produced in the intestinal
mucosa as well as in the hindbrain in response to nutrient
ingestion. This gut-brain hormone reduces food intake as
well as regulates glucose homeostasis, foremost via GLP-1
receptors in hypothalamus and brain stem. However,
GLP-1 receptors are expressed in areas intimately associ-
ated with reward regulation. Given that regulation of food
and drug intake share common neurobiological substrates,
the possibility that ghrelin and GLP-1 play an important
role in reward regulation should be considered. Indeed, this
leading article describes that the orexigenic peptide ghrelin
activates the cholinergic–dopaminergic reward link, an
important part of the reward systems in the brain associated
with reinforcement and thereby increases the incentive
salience for motivated behaviors via this system. We also
review the role of ghrelin signaling for reward induced by
alcohol and addictive drugs from a preclinical, clinical and
human genetic perspective. In addition, the recent findings
showing that GLP-1 controls reward induced by alcohol,
amphetamine, cocaine and nicotine in rodents are over-
viewed herein. Finally, the role of several other appetite
regulatory hormones for reward and addiction is briefly
discussed. Collectively, these data suggest that ghrelin and
GLP-1 receptors may be novel targets for development of
pharmacological treatments of alcohol and drug
dependence.
Key Points
The data presented in this leading article collectively
show that the orexigenic peptide ghrelin actives the
cholinergic–dopaminergic reward link, an important
part of the reward systems in the brain, implying that
ghrelin may increase the incentive salience of
motivated behaviors.
Central ghrelin signaling, as shown by ghrelin
administration, ghrelin knockout mice as well as by
pharmacological or genetical suppression of the
ghrelin receptor (GHS-R1A), is required for alcohol
mediated behaviors as well as for drug-induced
reward in rodents, which is verified in human
genetics studies.
In addition to regulation of food intake and glucose
homeostasis, recent and novel data show that
glucagon-like-peptide 1, another endocrine signal
from the gut, mediates reward induced by alcohol,
amphetamine, cocaine and nicotine in rodents.
In conclusion, peptides regulating appetite, such as
ghrelin and GLP-1, may therefore constitute novel
targets for development of pharmacological
treatment strategies for addictive behaviors such as
alcohol use disorders.
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1 Appetite Regulating Peptides
As discussed in several previous reviews, food intake and
appetite are regulated by various circulating hormones and
neuropeptides (see e.g. [1–3]). These signals include those
produced by the gastrointestinal tract, such as ghrelin,
peptide YY (3–36), oxyntomodulin, cholecystokinin and
glucagon-like peptide-1 (GLP-1), in the brain, including
galanin, orexin, neuropeptide Y (NPY), as well as those
produced by adipose tissue e.g. adiponectin, leptin, inter-
leukin-6 (for review see e.g. [2, 3] for overviews). Inter-
estingly, these hunger-controlling hormones inform the
present energy homeostasis to diverse neurobiological
circuits, especially the hypothalamus, causing a physio-
logical response (for review see e.g. [2, 3] for overviews).
For several of these hunger-regulating hormones an
increasing number of data, as reviewed herein, show that
they also target brain areas intimately associated with
reward and addiction. Taken together with the findings that
regulation of food and drug intake share common neuro-
biological substrates [4, 5], the possibility that endocrine
signals from the gut traditionally known to regulate food
intake, energy and body weight homeostasis may play a
role in reward regulation should be considered. Given that
ghrelin and GLP-1 are fairly new modulators of drug-
induced reward the involvement of these appetite-regulat-
ing peptides in reward and addiction processes are
reviewed in this leading article. In addition, the role of
several other hunger hormones in drug related behaviors is
briefly discussed.
2 Ghrelin
2.1 An Overview of Ghrelin and Its Function Within
the Central Nervous System
Ghrelin, a 28-amino acid peptide, is mainly produced in
and secreted from the stomach and other peripheral tissues
[6]. However, there might be some production in parts of
the brain [7–9]. Ghrelin was initially found to be involved
in the hypothalamo-pituitary growth axis by increasing the
release of growth hormone [6]. Extensive research has
since then shown that circulating ghrelin has physiological
roles for food intake and appetite in rodents as well as in
humans [1, 10–12]. In addition, ghrelin regulates meal
initiation [13] and increased ghrelin levels correlate with
hunger scores in healthy subjects [14]. The findings that
ghrelin increases adiposity by a mechanism that includes
decreased fat utilization [15, 16] suggested that ‘‘ghrelin
receptors’’ [i.e. growth hormone secretagogue receptor
(GHS-R1A)] could be pharmacological targets for
treatment of obesity. Hypothalamic GHS-R1A were readily
attributed to the ability of ghrelin to cause a release of
growth hormone, but these receptors were later found to be
important for ghrelin’s effect on fat accumulation, food
intake as well as energy balance [7]. Interestingly, ghrelin
and its receptor have since then been attributed several
other physiological roles. Thus, this hormone regulates
glucose levels, stimulates prolactin secretion, influences
sleep and acts on the cardiovascular system (for review see
[17]) and stimulates gastric motility in rodents [18]. In
addition, ghrelin influences memory formation via hippo-
campal GHS-R1A [19] and increases anxiety- and
depression-like behavior in rodents [20]. The findings that
GHS-R1A are expressed throughout the reward systems
[21–23], raised the hypothesis that ghrelin may have a role
in reward regulation.
2.2 Ghrelin Activates the Cholinergic–Dopaminergic
Reward Link
An important part of the reward systems in the brain is the
cholinergic–dopaminergic reward link. It encompasses a
cholinergic afferent projection from the laterodorsal teg-
mental area (LDTg) onto the ventral tegmental area (VTA)
dopamine cells together with the mesolimbic dopamine
system [i.e. the dopamine neurons from the VTA to
nucleus accumbens (NAc)] (for review see [24]). This
reward link is intimately associated with the reinforcing
properties of natural rewards and addictive drugs [25–28]
(for review see [24, 29]). The data presented in this leading
article collectively show that ghrelin actives the choliner-
gic–dopaminergic reward link, implying that ghrelin may
increase the incentive salience of motivated behaviors (for
overview see Table 1).
The first study showing that ghrelin activates the reward
systems showed that intracerebroventricular administration
of ghrelin increased accumbal dopamine release and
caused a locomotor stimulation in mice [30]. These data
were extended and corroborated by the findings showing
that local infusion of ghrelin into either the VTA or LDTg
causes a locomotor stimulation and accumbal dopamine
release [31] and that ghrelin administration locally into the
VTA increases the dopamine turnover in NAc in rodents
[32]. Furthermore, it was recently showed that peripheral
or intra-LDTg ghrelin administration concomitantly
increases ventral tegmental acetylcholine as well as ac-
cumbal dopamine release and that this synchronous neu-
rotransmitter release is blocked by systemic injection of a
GHS-R1A antagonist [33]. The findings that GHS-R1A are
expressed on cholinergic cells in the LDTg [34] as well as
on dopaminergic neurons in the VTA [32] further support
that ghrelin can activate the reward systems via local
mechanisms within the VTA and LDTg. A possibility that
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Table 1 Summary of articles addressing the role of ghrelin and GLP-1 signaling in alcohol and drug addiction
Ghrelin administration ? Activates the mesolimbic dopamine system, specifically the
cholinergic–dopaminergic reward link, in rodents
Jerlhag et al. [30]
Abizaid et al. [32]
Jerlhag et al. [31]
Jerlhag [36]
Jerlhag et al. [41]
Quarta et al. [37]
Jerlhag et al. [38]
Jerlhag et al. [33]
? Causes a focal activation of a network including ventral tegmental area,
nucleus accumbens and lateral hypothalamus in rats
Wellman et al.
[39]
? Increases novelty seeking in rats Hansson et al.
[50]
? Increases alcohol intake in mice when administered into the third ventricle,
ventral tegmental area or laterodorsal tegmental area
Jerlhag et al. [55]
? Slightly increases alcohol intake in alcohol naı¨ve rats when administered peripherally Lyons et al. [61]
? Augments cocaine-induced hyperlocomotion and conditioned place preference in rats Wellman et al.
[86]
Davis et al. [87]
? Increases the response in reward-related areas, such as nucleus accumbens, to food in humans Malik et al. [40]
? Increases alcohol craving in alcohol dependent heavy-drinking individuals when injected intravenously Leggio et al. [82]
Ghrelin knockout mice ? Display attenuation of alcohol-induced reward as measured by locomotor stimulation, conditioned
place preference and accumbal dopamine release
Jerlhag et al. [60]
Bahi et al. [57]
Prevention of ghrelin penetration
into the brain
? Does not alter the rewarding properties of alcohol or alcohol intake in rodents Jerlhag et al. [62]
Plasma levels of ghrelin ? Are not different in high- and low-alcohol preferring rats Landgren et al.
[56]
? Are lower in high-alcohol preferring rats than in low-alcohol preferring rats Szulc et al. [77]






? Which are increased by fasting are suppressed by acute intravenous administration
of alcohol in healthy nonsmoking social drinkers
Leggio et al. [73]
? Are suppressed in active drinking in alcohol-dependent individuals Addolorato et al.
[74]
Kraus et al. [76]
Badaoui et al.
[75]
? Are increased in abstinent alcoholics Kim et al. [78]
Kraus et al. [76]
Wurst et al. [79]
? Are higher in alcohol dependent individuals with high craving scores than
in those with low craving scores
Addolorato et al.
[74]
Wurst et al. [79]
Koopmann et al.
[80]
Leggio et al. [81]
? Are increased in rats with high reinstatement of cocaine-seeking behavior Tessari et al. [88]
Polymorphisms in ghrelin related
genes












? Are associated with high sucrose intake Landgren et al.
[68]
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ghrelin-induced reward could involve accumbal GHS-R1A
should also be considered since GHS-R1A are expressed in
this reward area [23].
Albeit ghrelin mainly is produced in the gastrointestinal
tract [6] the possibility that circulating ghrelin reaches
brain reward areas should be considered. Indeed, circu-
lating ghrelin passes the blood brain barrier [35] and
peripheral ghrelin administration induces a conditioned
place preference, causes accumbal dopamine release and
stimulates the locomotor activity in mice [36]. In support
of the possibility that circulating ghrelin has central ner-
vous effects are the findings showing that systemic ghrelin
administration increase dopamine in the shell, rather than
core, region of NAc [37]. The findings that VTA-infusion
of a GHS-R1A antagonist blocks the ability of peripheral
ghrelin to increase food intake [32] and activate the
mesolimbic dopamine system [38], suggest that, albeit
peripheral route of administration, the ability of ghrelin to
cause reward involves central nervous system. This is
further substantiated by imaging data revealing that
peripheral ghrelin administration causes a focal activation
of a network of VTA, NAc and lateral hypothalamus in
rats [39]. In healthy volunteers systemic ghrelin adminis-
tration increases the response in reward related areas such
as NAc to visual food as shown in human functional
magnetic resonance studies [40] (for overview see
Table 1).
The mechanisms regulating the ability of ghrelin to
active the cholinergic–dopaminergic reward link are being




? Blocks the rewarding properties of alcohol in mice when administered centrally or peripherally Jerlhag et al. [55]





Bahi et al. [57]
Suchankova et al.
[59]
? Decreases the motivation to consume alcohol as well as prevents relapse to alcohol drinking in rats Landgren et al.
[56]
? Blocks the rewarding properties of amphetamine, cocaine or nicotine in rodents Jerlhag et al. [89]







? Display attenuation of the rewarding properties of alcohol as measured by locomotor stimulation, accumbal
dopamine release as well as conditioned place preference
Jerlhag et al. [55]
? Display a reduction in cocaine-induced locomotor stimulation and sensitization Clifford et al.
[90]
Abizaid et al. [91]
Ghrelin receptor (GHS-R1A)
expression
? Is detected in the nucleus accumbens, amygdala as well as on dopaminergic neurons in the ventral tegmental
area and on cholinergic neurons in the laterodorsal tegmental area in rats





Cruz et al. [66]
















? Prevent nicotine reward as well as block nicotine-induced expression of locomotor sensitization in mice Egecioglu et al.
[118]
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(a3b2, b3 and a6) of the nicotinic acetylcholine receptor
expressed within the VTA are crucial for ghrelin-induced
reward [41]. Interestingly, antagonists to these subtypes
also attenuate the reinforcing properties of alcohol in
rodents [42–45] and reduce alcohol intake in heavy-
drinking smokers [46, 47]. The findings that the ability of
LDTg-ghrelin to increase accumbal dopamine is attenuated
by an unselective nicotinic acetylcholine receptor antago-
nist into the VTA [33], further strengthen the contention
that ghrelin activates the cholinergic–dopaminergic reward
link. Other neurotransmitters may however be important
for ghrelin-induced reward since the activity of mesolimbic
dopaminergic neurons is controlled by various afferents. In
support are the findings that a NMDA receptor antagonist,
but not orexin or opioid receptor antagonist, attenuates
ghrelin’s ability to increase accumbal dopamine release,
condition a place preference and cause a locomotor stim-
ulation in mice [38]. Ghrelin increased food reward is
modulated by NPY Y1 and opioid receptors in mice [48].
The findings that the mesolimbic dopamine system
increases the incentive salience of motivated behaviors
[49] and that ghrelin increases novelty seeking behavior in
rodents and men [50] collectively imply that ghrelin sig-
naling may influence the rewarding and motivational
properties of addictive drugs and behavior.
2.3 The Role of Ghrelin Signaling in Alcohol
Addiction
The findings that food deprivation augments drug rein-
forcement as well as increase self-administration of
addictive drugs in rodents [51, 52] further support the
hypothesis that common neurobiological mechanisms
regulate food and drug reward [4, 5]. This is further
substantiated by the findings that co-morbidities between
alcohol use disorder and compulsive over eating in
humans are common [53, 54]. As reviewed herein ghrelin,
and its receptor have been suggested to be a gut-brain
hormone of importance for addiction (for overview see
Table 1).
The first indication that ghrelin signaling regulates
alcohol intake was from a study showing that peripheral or
central administration of GHS-R1A antagonists (JMV2959
or BIM28163 respectively) reduces the intake of alcohol in
mice consuming alcohol for 12 weeks [55]. In accordance
are the findings that JMV2959 reduces high alcohol con-
sumption in high-alcohol consuming Wistar as well as in
alcohol-preferring (AA) rats [56], decreases voluntary
alcohol consumption and preference in mice [57] and that
peripheral administration of another GHS-R1A antagonist,
D-Lys3-GHRP-6, reduces alcohol consumption in rats [58].
Moreover, acute systemic administration of the GHS-R1A
antagonist, JMV2959, decreases alcohol intake in rats
voluntarily consuming alcohol for two, five and ten months
and the ability of JMV2959 to reduce alcohol intake is
more pronounced over time [59]. It was also found that
repeated administration of JMV2959 decreased alcohol
intake without inducing tolerance or rebound increase in
alcohol intake after treatment termination [59]. Further
support for an important role for ghrelin signaling in
alcohol dependence are the findings that the GHS-R1A
antagonist (JMV2959) reduces the motivation to consume
alcohol as measured in the operant lever pressing model
[56] as well as prevents the alcohol deprivation effect
which reflects rebound drinking in rats [59]. In addition to
alcohol intake, it has been shown that suppressed GHS-
R1A function achieved by either genetical or pharmaco-
logical approaches (central or peripheral administration of
a GHS-R1A antagonist (BIM28163 or JMV2959 respec-
tively)) attenuates alcohol reward as measured by loco-
motor stimulation, conditioned place preference and
accumbal dopamine release in mice [55].
Studies have also shown that central ghrelin adminis-
tration, either into the third ventricle, the VTA or LDTg,
increases alcohol intake in rats [55]. In accordance are the
data showing that the alcohol-induced locomotor stimula-
tion and dopamine release in NAc are attenuated in ghrelin
knockout mice compared to wild type mice [60]. These data
were later corroborated by others showing that ghrelin
knockout mice have a disrupted alcohol reward as measured
by locomotor stimulation, accumbal dopamine release and
conditioned place preference [57]. Peripheral ghrelin
administration only slightly increases alcohol intake in mice
voluntarily consuming alcohol for only 3 days [61] imply-
ing that ghrelin signaling is more important in rodents
exposed to alcohol for longer, rather than shorter, periods of
time. Recent data show that Spiegelmer NOX-B11-2, which
binds and neutralizes active (i.e. acylated) ghrelin in the
periphery with high affinity and thus prevents its brain
access, does not attenuate alcohol-induced reward in mice
nor alcohol intake in rats [62], suggesting that circulating
ghrelin in the plasma does not regulate alcohol intake or the
rewarding properties of alcohol. On the contrary NOX-B11-
2 reduced food intake in rats supporting a role for circu-
lating ghrelin as a physiological regulator of food intake
[62]. Given that ghrelin levels in the plasma are associated
with alcohol craving (see later in Sect. 2.3) the possibility
that circulating ghrelin is important for craving rather than
reward should be considered. Taken together with the
findings that ghrelin is produced centrally [7–9] it may be
suggested that central ghrelin signaling regulates alcohol
reward and consumption.
While previous studies pinpointed hypothalamic GHS-
R1A to be important for ghrelin mediated food intake [12],
the findings that ghrelin increases alcohol intake via local
injections into either the VTA or LDTg [55], suggest that
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the cholinergic–dopaminergic reward link is important for
ghrelin signaling to regulate alcohol-mediated behaviors.
GHS-R1A expression in the VTA is down regulated in
high-compared to low-alcohol consuming rats supporting
such a contention [59]. It has been shown that GHS-R1A
alters the sensitivity of the mesolimbic dopamine system via
its ability to heterodimerize with dopamine D1- and D2-like
receptors [63, 64] as well as via its constitutive activity [65].
The possibility that ventral tegmental GHS-R1A, via such
mechanisms, reduces the ability of addictive drugs to acti-
vate the mesolimbic dopamine system and thereby plays an
important role for reward processes and for development of
alcohol use disorder should therefore be considered. Other
mechanisms or areas may also mediate the ability of GHS-
R1A to regulate reward. Expression of GHS-R1A has been
identified in other areas of the mesolimbic dopamine system
such as the amygdala [23, 66]. It was recently revealed that
ghrelin modulates GABAergic transmission in the rat
amygdala by increasing inhibitory postsynaptic potential
amplitudes in both naive and alcohol-dependent rats via
pre- and post-synaptic mechanisms. Specifically, acute
alcohol perfusion occluded the ghrelin-induced increase in
GABAergic transmission whereas after repeated alcohol
perfusion an enhanced ghrelin-induced inhibitory postsyn-
aptic potential was observed in naı¨ve, but not alcohol-
dependent rats. Application of GHS-R1A antagonists
revealed tonic facilitatory activity of the GHS-R1A on
GABAergic transmission in amygdala [66]. Further studies
have shown that acute central administration of ghrelin
increased serotonergic turnover as well as the expression of
serotonin receptors in the amygdala in mice [67], suggest-
ing that ghrelin signaling within the amygdala may regulate
anxiety like behaviors.
There is a possibility that the orexigenic peptide reduces
alcohol intake due to alcohol’s caloric rather than
rewarding properties. This appears less likely since the
GHS-R1A antagonist JMV2959 reduces the intake of sac-
charine, another reward without calories [68], suppresses
parameters strictly reflecting reward namely locomotor
stimulation and conditioned place preference [55] as well
as attenuates reward induced by other addictive dugs
without caloric content (see Sect. 2.4).
Studies showing alterations in plasma levels of ghrelin
in patients with alcohol dependence as well as in high-
and low-alcohol preferring rats support a role for ghrelin
signaling in alcohol mediated behaviors. Initially it was
shown that acute oral alcohol intake reduces the secretion
of ghrelin in healthy volunteers [69–71]. Interestingly, the
reduction of ghrelin by acute oral alcohol intake is not
affected by gastroprotective sucralfate, implying that the
appetite-stimulating effect of alcohol is not mediated by
ghrelin [72]. The findings that acute intravenous admin-
istration of alcohol in healthy nonsmoking social drinkers
suppresses fasting-induced increase in ghrelin, but does
not alter circulating ghrelin levels, suggest that alcohol
may act directly in the stomach by preventing the release/
secretion of ghrelin as well as via systemic effects in
humans [73]. In line are also the findings that active
drinking in alcohol-dependent individuals suppresses both
ghrelin levels and fundic ghrelin production [74–76]. In
support are the data from a rodent study showing that
high-alcohol preferring rats have lower plasma levels of
ghrelin than low-alcohol preferring rats do [77]. However
this was not verified in another study showing no differ-
ence between ghrelin levels in high- and low-alcohol
preferring rats [56]. In abstinent alcoholics several studies
have shown that the levels of ghrelin are increased [76,
78]. This was also shown in abstinent female alcoholics
[79]. Moreover, higher ghrelin levels correlate with higher
craving levels in patients with alcohol use disorder [74,
79], suggest that ghrelin may increase the incentive value
of motivated behaviors. Supportively, a recent study
demonstrated that the plasma concentration of active
ghrelin (previous studies have investigated total ghrelin)
was positively correlated to alcohol craving and that the
plasma levels of active ghrelin increased significantly
during early abstinence [80]. In support are the findings
showing that the baseline ghrelin levels correlate with
self-reported craving scores in alcohol dependent indi-
viduals and that blood ghrelin levels are increased in
alcohol dependent subjects who abstained from alcohol
when compared to non-abstinent alcohol dependent sub-
jects [81]. I in support of ghrelin playing a role in the
neurobiology of alcohol craving are the recent data
showing that intravenous administration of exogenous
ghrelin increases alcohol craving in alcohol-dependent
heavy-drinking individuals [82]. In addition, human
genetic data show that high alcohol consumption in
humans is associated with a single nucleotide polymor-
phism in the GHS-R1A gene [83]. Data from a cohort of
Swedish females with alcohol dependence show that
paternal alcohol dependence as well as with type II
alcohol dependence is associated with haplotypes of the
preproghrelin and GHS-R1A genes [84]. Moreover,
polymorphisms of the ghrelin signaling system are asso-
ciated with important personality traits of individuals with
alcohol dependence namely decreased self-directedness
and alterations in self-transcendence [85].
2.4 The Role of Ghrelin Signaling in Drug Dependence
Data from several publications reviewed herein suggest
that ghrelin signaling has an important role for reward in
general (for overview see Table 1). It was initially showed
that peripheral ghrelin administration augments cocaine-
induced locomotor stimulation [86] as well as conditioned
880 J. A. Engel, E. Jerlhag
place preference to cocaine in rats [87]. In accordance are
the data showing a positive correlation between elevated
levels of ghrelin and increased cocaine seeking behavior in
rats [88]. Pharmacological suppression of GHS-R1A by
means of JMV2959 reduces the rewarding properties of
amphetamine and cocaine as measured by locomotor
stimulation, accumbal dopamine release and conditioned
place preference [89]. In addition, either genetic or phar-
macologic suppression of GHS-R1A attenuates cocaine-
induced locomotor stimulation as well as sensitization in
rats [90, 91]. Food restriction, which elevates ghrelin levels
[92], augments amphetamine- and cocaine-induced hyper-
locomotion, enhances cocaine-seeking behavior and
increases self-administration of cocaine or amphetamine in
rats [51]. Furthermore, the GHS-R1A antagonist JMV2959
decreases the rewarding properties of nicotine [93] as well
as prevents nicotine induced locomotor sensitization in
rodents [94]. Human genetic data show an association
between a single nucleotide polymorphism in the GHS-
R1A gene and smoking as well as with amphetamine
dependence [84, 95]. Taken together a role of ghrelin and
its receptor in the reinforcing properties of addictive drugs
may be implied.
3 Glucagon-Like Peptide 1 (GLP-1)
3.1 A Brief Overview of GLP-1 and Its Function
Within the Central Nervous System
GLP-1 is produced in the intestinal L-cells [96] as well as
in the hindbrain [97] in response to nutrient ingestion
[98]. Increasing evidence shows that central or peripheral
GLP-1 administration reduces food intake in rodents and
man [99–103]. In addition, this incretin peptide [104]
regulates glucose-dependent insulin secretion [105], gas-
tric emptying and glucagon secretion [106, 107]. GLP-1
analogues have therefore been approved for treatment of
type II diabetes. Initial studies showed that hypothalamic
as well as brainstem GLP-1 receptors are required for the
anorexic and glucoregulatory effects of GLP-1 [99, 108,
109]. The findings that GLP-1 receptors are expressed
through out the mesolimbic dopamine system [110] and
that GLP-1 containing neurons project directly to the
VTA and NAc [111], suggest that the role of GLP-1
extends beyond food intake and glucose regulation and
may include reward regulation as reviewed in this leading
article.
3.2 Role of GLP-1 in the Pathophysiology of Addiction
There are to date a few initial publications suggesting that
GLP-1 receptors have a role in reward regulation (for
overview see Table 1). Indeed, treatment with a GLP-1
analogue, exendin-4, at a dose with no effect per se,
prevented the rewarding properties of alcohol as measured
by locomotor stimulation and accumbal dopamine release
in mice [112]. This initial study also showed that condi-
tioned place preference, reflecting reward, for alcohol was
attenuated by both acute and chronic treatment with ex-
endin-4 in mice. Furthermore, exendin-4 treatment
decreased alcohol intake, using the intermittent access
20 % alcohol two-bottle-choice model, as well as reduced
alcohol seeking behavior, using the progressive ratio test
in the operant self-administration model, in rats [112].
These novel data imply that GLP-1 receptors could be
pharmacological targets for treatment of alcohol depen-
dence in man. The findings were later corroborated by
others showing that exendin-4, by peripheral or local
VTA infusion, decreases alcohol intake in rats and that
systemic exendin-4 injection attenuated alcohol induced
conditioned place preference in mice [113]. Moreover,
gastric bypass, which reduces ghrelin and increases GLP-
1 plasma levels, reduces alcohol intake in both humans
and rats [114]. In addition to alcohol, GLP-1 receptors
appear to be important for reward induced by addictive
drugs. Indeed, exendin-4 attenuates amphetamine-induced
locomotor stimulation and cocaine-induced conditioned
place preference in rodents [115, 116]. In support are the
recent data showing that exendin-4, attenuates the rein-
forcing properties of cocaine as well as amphetamine as
measured by locomotor stimulation, accumbal dopamine
release and conditioned place preference in mice [117]. In
accordance are the findings that exendin-4, in addition to
preventing nicotine reward, blocks nicotine-induced
expression of locomotor sensitization in mice [118]. To
investigate the role of GLP-1 receptors for drug addiction
further additional studies are warranted. For instance the
role of other GLP-1 analogues, including liraglutide and
exendatide, on alcohol reward, alcohol intake, relapse to
alcohol drinking, cue-induced relapse drinking should be
investigated. In addition, the role of the enzyme, dipep-
tidyl peptidase-4, which eliminates GLP-1, for alcohol-
and drug-induced reward should be elucidated. Associa-
tions between plasma levels of GLP-1 and alcohol craving
as well as alcohol use disorder should be studied. Asso-
ciations between polymorphisms in GLP-1 related genes
and alcohol dependence should be examined in human
genetic studies. Given that GLP-1 analogues, such as
exenatide and liraglutide, are approved for the treatment
of diabetes type II these reviewed data are of clinical
interest since GLP-1 analogues could be used in treatment
of drug dependence. When used for addiction therapy the
possibility that a reduced alcohol intake is driven by
nausea, rather than abolished reward, should be consid-
ered. Reports show that treatment with GLP-1 analogues
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is associated with an increased risk of pancreatitis, which
may be a concern for patients with alcohol use disorder
whom already display a risk for pancreatitis. Another
concern may be that these substances are administered by
subcutaneous injection.
4 Other Appetite-Regulating Hormones and Drug
Related Behaviors
In addition to ghrelin and GLP-1 several other gut-brain
hormones traditionally known to control food intake have
been shown to modulate the responses to drugs of abuse. In
brief, inhibition of leptin pathways decreases preference for
alcohol [119] and leptin increases alcohol intake [120] as
well as enhances the motivation to consume alcohol fol-
lowing alcohol withdrawal [121]. Elevated leptin levels
have been demonstrated in male alcoholics [122] as well as
in high alcohol-preferring mice [123]. Initial studies
showed that an orexin receptor antagonist reduced self-
administration of alcohol, prevents reinstatement of alco-
hol-seeking induced by both visual and olfactory cues in
alcohol preferring rats [124] as well as attenuates stress-
induced reinstatement for alcohol-seeking in Long-Evan
rats [125]. Activation of orexin neurons is associated with
context-driven renewal of alcohol-seeking in rats [126].
However, as reviewed elsewhere the role of orexin for
alcohol-induced reward appears to be more complex (for
review see [127]). Central administration of orexin rein-
states cocaine, morphine as well as heroin seeking behavior
[128–130]. In human studies, the plasma levels of the
anorexigenic peptides leptin as well as orexin are associ-
ated with nicotine craving [131]. Administration of either
of these peptides blocks reward induced by psychostimu-
lant drugs [132–134]. It was initially shown that NPY-
deficient mice show increased alcohol consumption, com-
pared with wild-type mice [135]. In addition, a NPY2
antagonist suppresses alcohol intake in both naı¨ve [136]
and postdependent animals [137]. Local infusion of a viral
vector designed to overexpress NPY into the amygdala
reduces alcohol intake [138]. Moreover, NPY blocks the
reinstatement of alcohol-seeking induced by yohimbine in
rats [139]. The serum levels of adiponectin are significantly
elevated in patients with alcohol dependence at admission
for alcohol detoxification as well as after one week of
withdrawal treatment [140]. This study also showed that
alcohol craving was significantly associated with adipo-
nectin [140]. In addition, cholecystokinin decreases alcohol
intake in rodents [141–143]. In accordance are the data
showing that a selective cholecystokinin-A receptor
antagonist reduced the consumption of alcohol, whereas a
specific cholecystokinin-B receptor antagonist decreases
the intake of cocaine in rats [144]. In addition, central
administration of the orexigenic peptide galanin increases
whereas a galanin antagonist reduces alcohol intake in rats
[145, 146].
5 Conclusion
Alcohol use disorder is one of the major causes of illness
and death in society, and the economic costs are extensive
(for review see [147, 148]). Today, only a few medications
are approved for treatment of alcohol dependence and
clinical trials suggest that the effect of these pharmaco-
logical agents is moderate (for review see [147, 148]).
Furthermore, it is a heterogenous disorder where treatment
possibly should be individualized. There is therefore a need
for additional and more effective medications. This leading
article presents a review of the data showing that gut-brain
peptides such as ghrelin and GLP-1 appear to have a
broader role than body weight homeostasis. Indeed, these
hormones regulate alcohol as well as drug-induced reward
and both GHS-R1A and GLP-1 receptors may therefore
constitute novel targets for development of pharmacologi-
cal treatment strategies for addictive behaviors such as
alcohol use disorders.
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